Effect of Sclerovit on endothelial dysfunction, hemorheological parameters, platelet aggregation, plasma concentration of homocysteine and progression of atherosclerosis in patients with vascular diseases.
In our prospective study the effect of Sclerovit (0.8 mg folic acid, 20 mug vitamin B12,5 mg vitamin B6,100 mg vitamin E) on inflammatory markers, hemorheological parameters, platelet aggregation, von Willebrand factor activity as a marker of endothelium dysfunction, plasma lipids, plasma levels of folic acid, vitamin B12 and homocysteine (hcy), flow mediated vasodilatation (FMD) and thickness of carotis intima-media after 1 and 6 months of treatment in patients with vascular diseases (10 patients took 1 capsule, 10 patients 2 capsules of Sclerovit and 10 patients placebo) was determined.Plasma level of vitamin B12, folic acid and elongation index of red blood cells (RBC) increased significantly (p<0.05-0.001), hcy and triglyceride concentrations decreased significantly (p<0.05-0.001) in patients taking Sclerovit. HDL-cholesterol, RBC count, hematocrit, plasma and whole blood viscosity increased significantly (p<0.05-0.001) both in patients taking placebo or vitamins. Fibrinogen and CRP showed a significant (p<0.05-0.01) increase in patients on placebo, but did not change in patients on Sclerovit therapy. FMD showed a significant (p<0.05) amelioration in patients on 1 capsule of Sclerovit.Beside the favorable effects of Sclerovit on some of the measured parameters, the observed deterioration in hemorheological parameters can correlate with the contradictory results of large prospective studies with vitamins.
Department of Medicine, Division of Cardiology, Medical School, University of Pecs, Pecs, Hungary.
Beata
B
Horvath
Laszlo
L
Szapary
Laszlo
L
Debreceni
Gergely
G
Feher
Peter
P
Kenyeres
Adrienn
A
Fulop
Istvan
I
Battyani
Kalman
K
Toth
D000368:Aged; D050197:Atherosclerosis / Q000097:blood / Q000188:drug therapy; D016893:Carotid Stenosis / Q000097:blood* / Q000188:drug therapy*; D004338:Drug Combinations; D004907:Erythrocyte Deformability / Q000187:drug effects; D005260:Female; D005492:Folic Acid / Q000627:therapeutic use*; D018056:Hemorheology / Q000187:drug effects*; D006710:Homocysteine / Q000097:blood* / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects*; D017539:Tunica Intima / Q000187:drug effects / Q000473:pathology; D017540:Tunica Media / Q000187:drug effects / Q000473:pathology; D014664:Vasodilation / Q000187:drug effects; D014805:Vitamin B 12 / Q000627:therapeutic use*; D025101:Vitamin B 6 / Q000627:therapeutic use*; D014810:Vitamin E / Q000627:therapeutic use*; D014841:von Willebrand Factor / Q000187:drug effects
D004338:Drug Combinations; C542335:sclerovit; D014841:von Willebrand Factor; D006710:Homocysteine; D014810:Vitamin E; D025101:Vitamin B 6; D005492:Folic Acid; D014805:Vitamin B 12